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Abstract
Introduction: The aim of this study was to investigate the association between exposure to cosmetics, often
containing mineral oil, and the risk of developing rheumatoid arthritis (RA). The study was performed against the
background that occupational exposure to mineral oil has recently been shown to be associated with an increased
risk for RA in man, and that injection of or percutaneous exposure to mineral-oil-containing cosmetics can induce
arthritis in certain rat strains.
Methods: A population-based case-control study of incident cases of RA was performed among the population
aged 18 to 70 years in a defined area of Sweden during May 1996 to December 2003. A case was defined as an
individual from the study base, who received for the first time a diagnosis of RA according to the 1987 American
College of Rheumatology criteria. Controls were randomly selected from the study base with consideration taken
for age, gender and residential area. Cases (n = 1,419) and controls (n = 1,674) answered an extensive
questionnaire regarding environmental and lifestyle factors including habits of cosmetic usage. The relative risk of
developing RA was calculated for subjects with different cosmetic usage compared with subjects with low or no
usage. Analysis was also performed stratifying the cases for presence/absence of rheumatoid factor and antibodies
to citrulline-containing peptides.
Results: The relative risks of developing RA associated with use of cosmetics were all close to one, both for
women and men, for different exposure categories, and in relation to different subgroups of RA.
Conclusion: This study does not support the hypothesis that ordinary usage of common cosmetics as body
lotions, skin creams, and ointments, often containing mineral oil, increase the risk for RA in the population in
general. We cannot exclude, however, that these cosmetics can contribute to arthritis in individuals carrying certain
genotypes or simultaneously being exposed to other arthritis-inducing environmental agents.
Introduction
Rheumatoid arthritis (RA) is a disease that is dependent
on genetic as well as environmental factors, as seen
from both concordance data in twins and from a num-
ber of epidemiological and genetic studies [1,2].
Whereas knowledge of the genetic basis of this disease
is rapidly advancing [3-5], there is a scarcity of data on
environmental agents that may cause arthritis [6-9]. In
particular, very little information exists in humans on
environmental factors with a known capacity to induce
arthritis in experimental arthritis systems.
Agents that are able to induce experimental arthritis
in animals, particularly in rats, include a number of
adjuvants originating from microbes such as bacteria,
yeast and viruses [10,11] as well as from other sources
such as mineral oils [12-14]. Arthritis may develop in
certain strains of rats after exposure to adjuvants both
intracutaneously and percutaneously [15]. The exact
mechanisms involved in the pathogenesis of these adju-
vant arthritis models are still not completely understood,
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but we know that mineral oil can activate cells within
the lymph nodes without causing any simultaneous
apparent inflammatory reaction in the skin [16]. In the
context of mineral oil, we investigated the arthritogenic
capacity of common cosmetics that are known to con-
tain high amounts of mineral oils, and we observed that
several such cosmetics could induce arthritis in the DA
strain of rats when administered subcutaneously as well
as percutaneously [16].
It has not been established whether similar mechan-
isms - that is, polyarthritis induced by simple adjuvants
- are operative also in human arthritis, although case
reports on arthritis development after adjuvant expo-
sures suggested that rodents and humans might both
react to adjuvants with arthritis development [17]. We
recently, however, used information obtained from a
large ongoing case-control study (Epidemiological Inves-
tigation of Rheumatoid Arthritis (EIRA)) to describe an
association between occupational exposure to mineral
oil and development of RA [18].
The combined observations from rodents on an
arthritogenic capacity of cosmetics containing mineral
oil, and the observation on mineral oils as a risk factor
also for human RA, mandated an investigation of
whether usage of cosmetics, often containing mineral
oil, is associated with an increased risk for RA. We also
used the large EIRA study for this purpose, utilising a
series of detailed questions to cases and controls on pre-
vious use of various cosmetics as skin creams, ointments
and body lotions. The level of exposure to mineral oil
via cosmetic use is probably essentially lower than the
level we previously analysed in the context of occupa-
tional exposure [18], but exposure via cosmetic use is
very common, especially among women, and even a
small increase in risk of RA might be of importance
from a public health perspective.
Materials and methods
The present study is a population-based case-control
study of incident cases of RA among the population
aged 18 to 70 years living in the central and southern
parts of Sweden during the period May 1996 to Decem-
ber 2003. Ethical permission was obtained from relevant
ethical committees and all participants (cases as well as
controls) consented to contribute to the study.
Case identification
A case was defined as a person in the study base who
for the first time received a diagnosis of RA according
to the 1987 American College of Rheumatology criteria
[19]. As described before [20], all potential cases were
examined and diagnosed by a rheumatologist at the
units entering cases into the study. All rheumatology
units linked to the general welfare system in the study
area participated in the study as well as almost all of
the, very few, privately-run rheumatology units. In total
there were 19 reporting clinics, 15 of which were Early
Arthritis Clinics [21]. At the start some centres also
reported cases that did not satisfy the criteria in order
to enable investigations of undifferentiated arthritis, but
these subjects were eventually excluded from the study.
Rheumatoid factor (RF) levels were determined locally
and reported as RF-positive or RF-negative. Anti-cyclic
citrullinated peptide (anti-CCP) antibodies were analysed
in a central laboratory (Department of Clinical Immunol-
ogy, Uppsala University Hospital) with the Immunoscan-
RA Mark2 ELISA test (Eurodiagnostica, Malmö, Sweden)
[22,23]. A level above 25 U/ml was regarded as positive
according to instructions in the kit and validation at the
clinical immunology laboratory in Uppsala.
Selection of controls
For each potential case, a control was randomly selected
from the study base matched on age, gender and resi-
dential area. The selection of controls was conducted
using the national population register, which is continu-
ously updated. If a control declined to participate, was
not traceable or reported having RA, a new control was
selected using the same principles (see also [20]). Con-
trols selected to cases that were excluded due to not ful-
filling the American College of Rheumatology criteria (n
= 255) remained in the study.
Data collection
Information about lifestyle and environmental exposures
was collected by questionnaire, an identical version
given to the cases shortly after they had been informed
about the RA diagnosis and sent by mail to the controls.
All questionnaires were supposed to be answered at
home.
Unanswered or incompletely answered questionnaires
were completed by mail or by telephone by purpose-
trained persons not connected to the rheumatology
clinics. This was done in an identical way for the case
and control groups. In all, we identified 1,480 cases and
2,038 controls for selection. Of these, 1,419 cases (1,012
women and 407 men) and 1,674 controls (1,188 women
and 486 men) participated in the study, giving a partici-
pation rate of 96% for cases and 82% for controls.
Exposure
The questionnaire contains questions within a wide
spectrum regarding personal circumstances including
lifestyle factors, occupational exposures, health aspects,
socio-economic factors, and demographic data. Specific
questions were asked about skin care habits in terms of
frequency of usage of cosmetic products as ointments,
skin creams and body lotions during the last 5 years.
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These questions were asked for different parts of the
body separately.
A global whole-body exposure measure was con-
structed by applying different scores according to fre-
quency of use. In this whole-body exposure measure,
each part of the body received the same weight (Table 1).
For each person, the scores for their five different body
regions were added. The whole-body exposure measure
was categorised into five different categories (A, 0 to 20;
B, 24 to 42; C, 48 to 64; D, 72 to 86; and E, 96 to 120)
with the aim to weight the score so that seldom use over
the whole body never got the same score as daily use on
one single part of the body (Table 2).
Potential confounding factors
All results were adjusted for age and residential area
according to the principle of control selection. In the
analyses, age was categorised into 10 strata (18 to 24, 25
to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54,
55 to 59, 60 to 64 and 65 to 70 years of age). Smoking
and occupational class were also considered as potential
confounding factors. Smoking was categorised into two
strata (never smokers and ever smokers) and occupa-
tional class was categorised into seven strata (unskilled
manual workers, skilled manual workers, assistant non-
manual employees, intermediate nonmanual employees,
higher nonmanual employees, self-employed and
farmers).
Statistical analysis
In the analysis, subjects who had been exposed to differ-
ent categories of use of cosmetics were compared with
subjects with no or low use (score 0 to 20) with regard
to the incidence of RF-positive RA, RF-negative RA,
anti-CCP-positive RA, anti-CCP-negative RA and RA
overall, respectively, by calculating the odds ratio
together with a 95% confidence interval. We performed
matched as well as unmatched analyses of the data.
Odds ratios, adjusted for potential confounding factors,
were calculated by means of conditional logistic regres-
sion in the matched analyses and by means of uncondi-
tional logistic regression in the unmatched analyses. We
only present results from the unmatched analyses as
these were in close agreement with those from the
matched analyses but, in general, had higher precision.
Odds ratios were interpreted as estimates of relative
risks as the study was population based [24]. Results for
women and men were analysed separately and in total.
Estimates of relative risk were adjusted for potential
confounding from age, gender (when appropriate), resi-
dential area, smoking and socio-economic class.
All analyses were performed using the Statistical Ana-
lysis System (version 8.2; SAS Institute, Stockholm,
Sweden).
Results
Of the 1,419 participating cases in this study, 1,012 were
women and 407 were men (mean age at inclusion 50 and
53 years, respectively). Among the female and male cases,
respectively, 65.5% and 66.3% were RF-positive and 61%
and 62% were anti-CCP-positive. The mean duration of
disease at inclusion in the study was 10 months.
Most women were regular users of cosmetics as body
lotions and skin creams. Only 10% of female controls
were low users. In contrast, most of the male controls
(74%) were low users.
When analysing the relationship between exposure to
skin care products and risk of developing RA, no
increased risk of developing RA in total was observed,
neither for women or for men; all observed relative risks
were close to 1 (Table 3). When the analysis was strati-
fied with regard to RF status for the cases, still no signs
of increased relative risks associated with cosmetic use
were observed (Table 4). On the contrary, the most
Table 1 Scoring of cosmetic exposure by frequency of
use and body region
Part of body Daily Every week Seldom Never
Face/neck 24 12 2 0
Hands 24 12 2 0
Legs 24 12 2 0
Feet 24 12 2 0
Body 24 12 2 0
Table 2 Exposure frequency of cosmetics, by gender and disease status
Women Men
Cosmetic exposure Cases Controls Total Cases Controls Total
Class Score n % n % n % n % n % n %
A 0 to 20 104 10.28 118 9.95 237 10.18 315 77.59 359 74.33 715 75.50
B 24 to 42 178 17.59 174 14.67 376 16.16 53 13.05 78 16.15 140 14.78
C 48 to 64 178 17.59 230 19.39 436 18.74 22 5.42 27 5.59 55 5.81
D 72 to 86 319 31.52 370 31.20 729 31.33 12 2.96 13 2.69 26 2.75
E 96 to 120 233 23.02 294 24.79 549 23.59 4 0.99 6 1.24 11 1.16
Total 1,012 1,186 2,327 406 483 947
Sverdrup et al. Arthritis Research & Therapy 2012, 14:R41
http://arthritis-research.com/content/14/1/R41
Page 3 of 7
heavily exposed category was associated with a 30%
decreased risk of RF-positive RA (relative risk = 0.7,
95% confidence interval = 0.5 to 1.0) (Table 4). A simi-
lar pattern was observed with regard to anti-CCP-posi-
tive RA, where the most exposed category was also
associated with a 30% decreased risk (relative risk = 0.7,
95% confidence interval = 0.5 to 1.0) (Table 5).
Discussion
The results of this study provide no evidence that
women or men exposed to common cosmetics as skin
creams, ointments or body lotions have an increased
risk of developing RA.
Our study has the advantage of being a population-
based case-control study using only incident cases of
newly diagnosed RA, fulfilling the American College of
Rheumatology criteria as assessed by a specialist in
rheumatology. To minimise recruitment bias, we took
advantage of the fact that almost all healthcare in Swe-
den is provided within the general healthcare system,
and that all such units in the area that defined the study
base contributed to the study, as did almost all of the
few privately-run rheumatology units. Still, some cases
may have been unidentified in our study; for instance,
cases diagnosed in primary healthcare facilities that
were never referred to a rheumatology unit. We know
from population-based studies aimed at identifying RA
cases directly in primary care, however, that almost all
Table 3 Relative risk of developing rheumatoid arthritis
















A 104/118 1.0 Reference 1.0 Reference
B 178/174 1.1 0.8 to 1.6 1.0 0.7 to 1.5
C 178/230 0.9 0.6 to 1.2 0.8 0.6 to 1.2
D 319/370 1.0 0.7 to 1.3 0.9 0.6 to 1.2
E 233/294 0.9 0.6-1.2 0.8 0.5 to 1.1
Men
A 315/359 1.0 Reference 1.0 Reference
B 53/78 0.7 0.5 to 1.1 0.8 0.5 to 1.2
C 22/27 0.8 0.5 to 1.5 0.9 0.5 to 1.6
D 12/13 1.1 0.5 to 2.5 1.1 0.5 to 2.5
E 4/6 0.9 0.2 to 3.2 0.6 0.1 to 2.6
All
A 419/477 1.0 Reference 1.0 Reference
B 231/252 0.9 0.7 to 1.2 0.9 0.7 to 1.2
C 200/257 0.9 0.7 to 1.2 0.8 0.6 to 1.1
D 331/383 1.0 0.7 to 1.3 0.9 0.7 to 1.2
E 237/300 0.9 0.6 to 1.2 0.8 0.5 to 1.1
Relative risk together with 95% confidence interval of developing rheumatoid
arthritis overall for subjects 18 to 70 years old reporting different amounts of
exposure to cosmetics compared with those low exposed (A), by gender.
aAdjusted for age, living area and gender where appropriate. bAdjusted for age,
living area, gender, socio-economic status and smoking where appropriate.
Table 4 Relative risk of developing RF-positive and RF-negative rheumatoid arthritis for subjects reporting exposure
to cosmetics
RF+RA RF-RA
Exposure Number of exposed
cases/controlsa
RRb 95% CI RRc 95% CI Number of exposed
cases/controlsa
RRb 95% CI RRc 95% C
Women Women
A 73/118 1.0 Reference 1.0 Reference 30/118 1.0 Reference 1.0 Reference
B 118/174 1.1 0.7-1.5 1.0 0.6-1.5 60/174 1.3 0.8-2.2 1.2 0.7-2.1
C 115/230 0.8 0.5-1.2 0.7 0.5-1.1 63/230 1.1 0.6-1.7 0.9 0.5-1.7
D 215/370 0.9 0.6-1.3 0.8 0.6-1.2 104/370 1.1 0.7-1.7 1.0 0.6-1.7
E 139/294 0.7 0.5-1.0 0.7 0.4-1.0 94/294 1.2 0.7-2.0 1.0 0.6-1.8
Men Men
A 212/359 1.0 Reference 1.0 Reference 103/359 1.0 Reference 1.0 Reference
B 31/78 0.6 0.4-1.0 0.7 0.4-1.1 22/78 1.0 0.6-1.6 1.0 0.6-1.8
C 14/27 0.8 0.4-1.6 0.8 0.4-1.6 8/27 0.9 0.4-2.1 1.0 0.4-2.3
D 7/13 1.0 0.4-2.5 1.0 0.4-2.7 5/13 1.3 0.5-4.0 1.3 0.4-4.1
E 3/6 0.8 0.2-3.3 0.5 0.1-2.8 1/6 1.0 0.1-9.0 0.9 0.1-9.1
All All
A 285/477 1.0 Reference 1.0 Reference 133/477 1.0 Reference 1.0 Reference
B 149/252 0.9 0.6-1.2 0.8 0.6-1.1 82/252 1.1 0.8-1.6 1.1 0.7-1.6
C 129/257 0.8 0.6-1.1 0.7 0.5-1.1 71/257 1.0 0.7-1.6 0.9 0.6-1.5
D 222/383 0.9 0.6-1.2 0.8 0.6-1.2 109/383 1.1 0.7-1.7 1.1 0.7-1.7
E 142/300 0.7 0.5-1.0 0.7 0.5-1.0 95/300 1.2 0.7-1.9 1.0 0.6-1.7
Relative risk (RR) together with 95% confidence interval (CI) of developing rheumatoid factor (RF)-positive rheumatoid arthritis (RA), and RF-negative RA for
subjects 18 to 70 years old reporting different amounts of exposure to cosmetics compared with those low exposed (A), by gender. aInformation on RF status is
missing for one female case in comparison with Table 3. bAdjusted for age, living area and gender where appropriate. cAdjusted for age, living area, gender,
socio-economic status and smoking where appropriate.
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cases of RA in our current Swedish system are indeed
referred to rheumatology units. The relatively few uni-
dentified cases would therefore probably not cause a
substantial bias in our calculations. The response rate in
the study was high, at 96% for cases and 82% for con-
trols, which limits risk for selection bias in this stage.
In our study, information on cosmetic use was based
on self-reported data about the frequency of cosmetic
use on different parts of the body, as reported in a ques-
tionnaire. A possible disadvantage with a case-control
study with retrospective collection of exposure data is
the risk of misclassification of exposure due to recall
bias. Only subjects that received a diagnosis of RA for
the first time were included in order to reduce the risk
of recall bias; the mean duration between the estimated
disease onset and inclusion into the study was 10
months. In light of the observed results, bias due to
nondifferential misclassification of cosmetic use could in
principle have led to diluted estimates of relative risks
and hence could have masked true positive associations.
The observation, in our data, of a tendency towards a
decreased risk of RA among those with the highest
exposure to cosmetics, however, makes unlikely the pos-
sibility that nondifferential misclassification of exposure
has masked a true positive association between cosmetic
use and RA. Still, there is a possibility that differential
misclassification may have done so. If cases underreport
true exposure to a higher extent than controls, this may
indeed be the case. We have no reason to believe that
this is the case, but this a possibility that cannot be
ruled out.
All results were adjusted for age and residential area
according to the principle of control selection. In the
analysis, we investigated the potential confounding from
smoking and socio-economic group. Adjustment for
these factors only marginally changed the estimated
relative risks.
In the analysis, subjects who had been exposed to skin
care products were compared with subjects with low use
(score 0 to 20). In theory, the preferred comparison
group should be totally unexposed (score 0). Among
women, less than 0.6% was totally unexposed to cos-
metics, which hampered the use of totally unexposed as
a reference category. Among men, on the contrary,
15.9% were nonusers. We performed analyses comparing
men exposed to cosmetics of various degrees with
totally unexposed men. Still, no increased risks asso-
ciated with cosmetic use were observed. Further, we did
perform separate analyses regarding use of skin care
products on different parts of the body (that is, face/
neck, hands, legs, feet, chest/back) and risk of RA, since
an association restricted to a specific part of the body
Table 5 Relative risk of developing anti-CCP-positive and anti-CCP-negative rheumatoid arthritis for subjects reporting
exposure to cosmetics
Anti-CCP-positive RA Anti-CCP-negative RA
Exposure Number of
exposed cases/controlsa
RRb 95% CI RRc 95% CI Number of exposed
cases/controlsa
RRb 95% CI RRc 95% CI
Women
A 65/118 1.0 Reference 1.0 Reference 38/118 1.0 Reference 1.0 Reference
B 110/174 1.1 0.7 to 1.7 1.0 0.7 to 1.6 68/174 1.2 0.7 to 1.9 1.1 0.6 to 1.9
C 106/230 0.8 0.6 to 1.2 0.8 0.5 to 1.2 68/230 0.9 0.6 to 1.5 0.9 0.5 to 1.5
D 199/370 0.9 0.6 to 1.3 0.8 0.6 to 1.2 116/370 0.9 0.6 to 1.4 0.9 0.6 to 1.4
E 130/294 0.7 0.5 to 1.1 0.7 0.4 to 1.0 100/294 1.0 0.6 to 1.6 0.9 0.5 to 1.5
Men
A 197/359 1.0 Reference 1.0 Reference 113/359 1.0 Reference 1.0 Reference
B 27/78 0.6 0.4 to 1.0 0.6 0.3 to 1.0 25/78 1.0 0.6 to 1.6 1.1 0.6 to 1.8
C 12/27 0.7 0.3 to 1.4 0.7 0.3 to 1.4 10/27 1.1 0.5 to 2.5 1.2 0.6 to 2.8
D 7/13 1.1 0.4 to 2.9 1.1 0.4 to 3.0 5/13 1.3 0.4 to 3.7 1.2 0.4 to 3.6
E 4/6 1.3 0.3 to 4.7 0.9 0.2 to 3.8 0/6 n.a. n.a. n.a n.a.
All
A 162/477 1.0 Reference 1.0 Reference 151/477 1.0 Reference 1.0 Reference
B 137/252 0.9 0.6 to 1.2 0.8 0.6 to 1.1 93/252 1.1 0.7 to 1.5 1.0 0.7 to 1.5
C 118/257 0.8 0.6 to 1.1 0.7 0.5 to 1.1 78/257 1.0 0.6 to 1.4 0.9 0.6 to 1.4
D 206/383 0.9 0.7 to 1.3 0.9 0.6 to 1.2 121/383 0.9 0.6 to 1.4 0.9 0.6 to 1.4
E 134/300 0.8 0.6 to 1.1 0.7 0.5 to 1.0 100/300 0.9 0.6 to 1.4 0.8 0.5 to 1.3
Relative risk (RR) together with 95% confidence interval (CI) of developing anti-cyclic citrullinated peptide-positive rheumatoid arthritis (RA) and anti-CCP-negative
RA for subjects 18 to 70 years old reporting different amounts of exposure to cosmetics compared with those low exposed (A), by gender. aInformation on anti-
CCP status is missing for 12 female and five male cases in comparison with Table 3. bAdjusted for age, living area and gender where appropriate. cAdjusted for
age, living area, gender, socio-economic status and smoking where appropriate.
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may be hidden by the use of a global exposure measure.
For none of the five specific parts of the body was an
association seen.
To increase the interpretability of negative studies, as
the current one, it is of interest to know the power of
the study, or what magnitude of risk difference between
the exposed and unexposed the study reasonably would
detect. The size of the current study was sufficient
(power > 0.80) to detect a risk increase in the order of
20 to 30% (for women and men taken together).
In 1998 we reported of induction of arthritis in the
DA rat by common cosmetic products available at stores
and pharmacies [16]. In the rat experiments we had
chosen common commercial products with a general
high share of mineral oil. The exact composition of the
products, however, was not publicly available, neither in
1998 or today. The cosmetics, containing mineral oil,
used in the experimental induction of arthritis, however,
still contain mineral oil according to their actual
declaration of ingredients. Besides, the most evident ani-
mal arthritis was induced by intradermal injection. The
experimental arthritis induced by percutaneous adminis-
tration on abrased skin was mild and of short duration;
the corresponding human transient arthritis would very
probably pass without any registration as early arthritis
or RA. We therefore cannot exclude that a few indivi-
duals exposed to both skin trauma and certain mineral-
oil-containing cosmetics may develop arthritis, but this
is unlikely to be a common event.
We recently reported an association between occupa-
tional exposure to mineral oil and RF-positive RA and
anti-CCP-positive RA, respectively, among men [18].
The male occupational exposure to mineral oil probably
comprises both larger quantities and higher concentra-
tion of mineral oil than is the case during use of cos-
metics, and, in addition, occupational exposure to
mineral oil may often occur with simultaneous damage
of the skin.
In summary, even though occupational exposure to
mineral oil seems to be associated with an increased
risk of RA, the use of skin care products - with contents
of those during the late 1990s and before - does not
seem to be a risk factor for RA in the population in
general. Even though we cannot rule out that cosmetics
can contribute to arthritis in some individuals carrying
certain genotypes, our finding is thus of importance
from a public health perspective, and there is no basis
for a recommendation to avoid skin care products con-
taining the usual amounts of mineral oil.
Conclusion
This study does not support the hypothesis that ordin-
ary usage of body lotions, skin creams or ointments,
often containing mineral oil, increases the risk of RA in
the population in general. We cannot exclude, however,
the possibility that these cosmetics can contribute to
arthritis in individuals carrying certain genotypes or
simultaneously being exposed to other agents that con-
tribute to the development of arthritis.
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